Advancements in Sjögren’s Disease

CE / CME

Making Progress in Sjögren’s: Key Considerations for Improving Recognition, Disease Management, and the Potential of Emerging Therapies

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurse Practitioners: 1.00 Nursing contact hours, includes 1.00 hour of pharmacotherapy credit

Released: November 21, 2024

Expiration: November 20, 2025

R. Hal Scofield
R. Hal Scofield, MD

Activity

Progress
1 2
Course Completed

References

  1. National Institute of Dental and Craniofacial Research. Sjögren’s disease. nidcr.nih.gov/health-info/sjogrens-disease. Accessed November 4, 2024.
  2. Negrini S, Emmi G, Greco M, et al. Sjogren's syndrome: a systemic autoimmune disease. Clin Exp Med. 2022;22:9-25.
  3. Sjögren’s Foundation. Sjögren’s fact sheet. sjogrens.org/sites/default/files/inline-files/Sjogrens%20Fact%20Sheet.pdf. Accessed November 4, 2024.
  4. Perera S, Ma L, Punwaney R, et al. Clinical and cost burden of primary Sjogren's syndrome: Descriptive analysis using a US administrative claims database. J Health Econ Outcomes Res. 2018;5:150-161.
  5. Vivino FB, Bunya VY, Massaro-Giordano G, et al. Sjogren's syndrome: An update on disease pathogenesis, clinical manifestations and treatment. Clin Immunol. 2019;203:81-121.
  6. Brito-Zeron P, Flores-Chavez A, Horvath IF, et al. Mortality risk factors in primary Sjogren syndrome: a real-world, retrospective, cohort study. EClinicalMedicine. 2023;61:102062.
  7. Fragkioudaki S, Mavragani CP, Moutsopoulos HM. Predicting the risk for lymphoma development in Sjogren syndrome: An easy tool for clinical use. Medicine (Baltimore). 2016;95:e3766.
  8. Carsons SE PB. Sjögren Syndrome. ncbi.nlm.nih.gov/books/NBK431049/. Accessed November 4, 2024.
  9. Kelly AL, Nelson RJ, Sara R, Alberto S. Sjogren syndrome: New insights in the pathogenesis and role of nuclear medicine. J Clin Med. 2022;11.
  10. Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349:1526-1533.
  11. Price EJ, Venables PJ. The etiopathogenesis of Sjogren's syndrome. Semin Arthritis Rheum. 1995;25:117-133.
  12. Mao J, Gomez GGF, Wang M, et al. Prediction of Sjogren's disease diagnosis using matched electronic dental-health record data. BMC Med Inform Decis Mak. 2024;24:43.
  13. Scofield RH, Sharma R, Pezant N, et al. American Indians have a higher risk of Sjogren's syndrome and more disease activity than European Americans and African Americans. Arthritis Care Res (Hoboken). 2020;72:1049-1056.
  14. Kassan SS, Moutsopoulos HM. Clinical manifestations and early diagnosis of Sjogren syndrome. Arch Intern Med. 2004;164:1275-1284.
  15. Vitali C, Minniti A, Pignataro F, et al. Management of Sjogren's syndrome: Present issues and future perspectives. Front Med (Lausanne). 2021;8:676885.
  16. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61:554-558.
  17. Yu K, Ying GS, Vivino FB, et al. Preliminary screening questionnaire for Sjogren's syndrome in the rheumatology setting. J Clin Rheumatol. 2022;28:e456-e461.
  18. Shiboski CH, Shiboski SC, Seror R, et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjogren's syndrome: A consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheumatol. 2017;69:35-45.
  19. Seror R, Ravaud P, Bowman SJ, et al. EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome. Ann Rheum Dis. 2010;69:1103-1109.
  20. Seror R, Ravaud P, Mariette X, et al. EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome. Ann Rheum Dis. 2011;70:968-972.
  21. Yoshimi R, Ueda A, Ozato K, Ishigatsubo Y. Clinical and pathological roles of Ro/SSA autoantibody system. Clin Dev Immunol. 2012;2012:606195.
  22. Danda D, Sharma R, Truong D, et al. Anti-La positive, anti-Ro negative subset of primary Sjogren's syndrome: anti-La is a reality but is the disease? Clin Exp Rheumatol. 2017;35:438-444.
  23. Baer AN, McAdams DeMarco M, et al. The SSB-positive/SSA-negative antibody profile is not associated with key phenotypic features of Sjogren's syndrome. Ann Rheum Dis. 2015;74:1557-1561.
  24. Lorenzon M, Spina E, Tulipano Di Franco F, et al. Salivary gland ultrasound in primary Sjogren's syndrome: Current and future perspectives. Open Access Rheumatol. 2022;14:147-160.
  25. Ramos-Casals M, Brito-Zeron P, Bombardieri S, et al. EULAR recommendations for the management of Sjogren's syndrome with topical and systemic therapies. Ann Rheum Dis. 2020;79:3-18.
  26. Gottenberg JE, Ravaud P, Puechal X, et al. Effects of hydroxychloroquine on symptomatic improvement in primary Sjogren syndrome: the JOQUER randomized clinical trial. JAMA. 2014;312:249-258.
  27. Wang E, Mi X, Thompson MC, et al. Mechanisms of resistance to noncovalent Bruton's tyrosine kinase inhibitors. N Engl J Med. 2022;386:735-743.
  28. Xu D, Fang J, Zhang S, et al. Efficacy and safety of telitacicept in primary Sjogren's syndrome: a randomized, double-blind, placebo-controlled, phase 2 trial. Rheumatology (Oxford). 2024;63:698-705.
  29. St Clair EW, Baer AN, Ng WF, et al. CD40 ligand antagonist dazodalibep in Sjogren's disease: a randomized, double-blinded, placebo-controlled, phase 2 trial. Nat Med. 2024;30:1583-1592.
  30. Bowman SJ, Fox R, Dorner T, et al. Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjogren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial. Lancet. 2022;399:161-171.
  31. Mariette X, Barone F, Baldini C, et al. A randomized, phase II study of sequential belimumab and rituximab in primary Sjogren's syndrome. JCI Insight. 2022;7.
  32. Kahlenberg J SI, Wu C,. Deucravacitinib reduces interferons, B cell pathways, and serological biomarkers of systemic lupus disease activity: pharmacodynamic analysis from the Phase 2 PAISLEY study. Arthritis Rheumatol. 2022;74:1978-1979.
  33. Balogh L, Olah K, Santa S, et al. Novel and potential future therapeutic options in systemic autoimmune diseases. Front Immunol. 2024;15:1249500.